andrew martin

andrew martin

ASCO 2015 - First Overall Survival Results from STAMPEDE

4d ago
SOURCE  

Description

Andrew Martin, MD, Biostatistician at NHMRC Clinical Trials Centre discusses docetaxel and/or zolendronic acid for hormone-naive prostate cancer and the first overall survival results of STAMPEDE at ASCO 2015. MDLinx Conference Coverage - 2015 ASCO Annual Meeting: http://www.mdlinx.com/conference-interview/asco-2015/index.cfm MDLinx: http://www.mdlinx.com/ Smartest Doc & Board Exam Prep: http://www.thesmartestdoc.com/ M3 USA: http://usa.m3.com/ Follow MDLinx: Facebook - https://www.facebook.com/MDLinx Twitter - https://twitter.com/MDLinx Google+ - https://plus.google.com/+Mdlinx/